640 Stock Chart & Stats
€0.49
€0.00(0.00%)
At close: 4:00 PM EST
€0.49
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.46 - €0.71
Previous CloseN/A
Volume0.00
Average Volume (3M)66.00
Market Cap
€3.37B
Enterprise Value€162.34K
Total Cash (Recent Filing)€31.05B
Total Debt (Recent Filing)€104.87B
Price to Earnings (P/E)6.8
Beta0.25
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding6,282,510,300
10 Day Avg. Volume0
30 Day Avg. Volume66
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)0.49
Price to Sales (P/S)0.09
P/FCF Ratio1.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Integrated Business Model (distribution, Retail, Manufacturing)Vertical integration across distribution, retail and manufacturing creates durable revenue diversification and supply‑chain control. This reduces dependence on single channels, enables margin capture across the value chain, supports cross‑selling and logistics scale advantages that persist over multiple years.
Strong Cash Generation And FCF QualityConsistently strong operating and free cash flow relative to earnings signals high earnings quality and internal funding capacity. Durable cash generation supports reinvestment, dividends and working capital needs, and provides a buffer against cyclical revenue swings over the coming 2–6 months and beyond.
Steady Revenue Growth With Improving Gross MarginConsistent top‑line expansion combined with recent gross margin improvement indicates the business is regaining pricing or mix advantages and executing operationally. This trend supports sustainable mid‑single‑digit growth and modest margin expansion, underpinning long‑term cash flow stability.
Bears Say
Rising Leverage (debt-to-equity ~1.83)Material increase in leverage weakens financial flexibility and raises refinancing and interest‑rate risks. Higher debt levels reduce capacity for strategic investment or acquisitive growth and make the company more vulnerable to credit tightening or margin shocks over a multi‑month horizon.
Very Thin Net Margins (~1–1.5%)Persistently low net margins constrain the ability to convert revenue growth into earnings and absorb cost inflation or margin pressure. Limited bottom‑line leverage reduces buffer to service higher debt and makes return volatility more likely if input costs or reimbursement dynamics worsen.
OCF Covers Only A Small Portion Of Total DebtAlthough cash flow is strong versus earnings, operating cash flow only covers a small fraction of total debt, slowing ability to materially reduce leverage. This structural mismatch limits balance‑sheet repair capacity and elevates risk if capital costs rise or access to credit tightens.
China Resources Pharmaceutical Group Ltd. News
640 FAQ
What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?
China Resources Pharmaceutical Group Ltd. lowest stock price was €0.46 and its highest was €0.71 in the past 12 months.
What is China Resources Pharmaceutical Group Ltd.’s market cap?
China Resources Pharmaceutical Group Ltd.’s market cap is €3.37B.
When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?
Currently, no data Available
Is China Resources Pharmaceutical Group Ltd. overvalued?
According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Overvalued.
Does China Resources Pharmaceutical Group Ltd. pay dividends?
China Resources Pharmaceutical Group Ltd. does not currently pay dividends.
What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?
China Resources Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?
China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.
What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?
Currently, no hedge funds are holding shares in DE:640
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
China Resources Pharmaceutical Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
-17.45%
12-Months-Change
Fundamentals
Return on Equity
4.65%
Trailing 12-Months
Asset Growth
2.12%
Trailing 12-Months
Company Description
China Resources Pharmaceutical Group Ltd.
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
Technical Analysis
The United Laboratories International Holdings
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―